White House Science Blueprint Prioritizes AI Over Life Sciences Research

The Trump administration unveiled a new science policy framework that would redirect hundreds of billions of research dollars from universities toward private industry, with emphasis on artificial intelligence development. This significant shift in federal funding priorities could reshape how medical and pharmaceutical research is conducted in the United States. The reallocation potentially affects funding for life sciences research that historically supported disease treatment and prevention studies. Healthcare researchers and institutions are evaluating how this policy change may impact ongoing clinical trials, drug development programs, and basic science investigations that benefit patients across multiple health conditions.